The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The potential of dual-antigen-targeting CAR T-cell therapies in myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, briefly discusses the potential of dual-antigen-targeting CAR T-cell therapies in myeloma, highlighting that this approach may decrease the risk of target antigen loss and increase response rates and duration of response in patients. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So clearly one of the issues of escape mechanisms or refractoriness or failing treatment with CAR T-cells is the loss of the target antigen. This has been shown for BCMA. It has also been shown for GPRC5D. So the hope is that by dual-targeting, we can decrease the risk of target antigen loss, decrease the options for a myeloma cell to become resistant to CAR T-cell therapy...
So clearly one of the issues of escape mechanisms or refractoriness or failing treatment with CAR T-cells is the loss of the target antigen. This has been shown for BCMA. It has also been shown for GPRC5D. So the hope is that by dual-targeting, we can decrease the risk of target antigen loss, decrease the options for a myeloma cell to become resistant to CAR T-cell therapy. So hopefully, it will increase also the response rate and the duration of response in our patients. So they are already… our product is still in the preclinical assessment, but there are several products that are now tested in the clinic already. It’s a BCMA and a GPRC5D targeting CAR-T product. And from another company, there’s also a BCMA and CD19 targeting CAR-T product in early clinical development. So already patients are receiving this product.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
